Search: (WFRF:(Cohen Ohad)) >
A European Cost-Uti...
A European Cost-Utility Analysis of the MiniMedTM 780G Advanced Hybrid Closed-Loop System versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes
-
- Jendle, Johan, 1963- (author)
- Örebro universitet,Institutionen för medicinska vetenskaper
-
- Buompensiere, Maria Ida (author)
- Medtronic International Trading Sarl, 30907, Tolochenaz, Vaud, Switzerland
-
- Ozdemir Saltik, Asli Zeynep (author)
- Medtronic, Market Access & Reimbursement, Saray Mh. Esnaf Sk. Akkom Ofis Park Laodik Plaza, No:2 Kat:3-4 Umraniye, Istanbul, Turkey
-
show more...
-
- de Portu, Simona (author)
- Medtronic International Trading S?rl, Rte du Molliau 31, Tolochenaz, Switzerland
-
- Smith-Palmer, Jayne (author)
- Covalence Research Ltd, 555181, Rivers Lodge, West Common, Harpenden, United Kingdom of Great Britain and Northern Ireland
-
- Pollock, Richard (author)
- Covalence Research Ltd, 555181, Harpenden, United Kingdom of Great Britain and Northern Ireland
-
- Cohen, Ohad (author)
- Medtronic International Trading Sàrl, Toluchenaz, Tolochenaz, Switzerland
-
show less...
-
(creator_code:org_t)
- Mary Ann Liebert, 2023
- 2023
- English.
-
In: Diabetes Technology & Therapeutics. - : Mary Ann Liebert. - 1520-9156 .- 1557-8593. ; 25:12, s. 864-876
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: Advanced hybrid closed-loop (AHCL) automated insulin delivery systems are the most effective therapy in terms of assisting people with type 1 diabetes (T1D) to achieve glycemic targets; however, the cost can represent a barrier to uptake. Here, a cost-utility analysis of the MiniMedTM 780G AHCL system (MM780G) versus intermittently-scanned continuous glucose monitoring (is-CGM) plus multiple daily insulin injections (MDI) in people with T1D not achieving glycemic goals was performed across six European countries.Methods: Clinical input data were sourced from the ADAPT trial. Assuming a baseline HbA1c of 9.04%, HbA1c reductions of 1.54% for AHCL and 0.2% for is-CGM+MDI were assumed. The analyses were performed from a payer perspective over a time horizon of 40 years and an annual discount rate of 3% was applied.Results: Across all countries, the use of AHCL was projected to result in an incremental gain in quality-adjusted life expectancy of >2 quality-adjusted life years (QALYs) versus is-CGM+MDI. Lifetime direct costs were higher with AHCL resulting in incremental cost-utility ratios for AHCL versus is-CGM+MDI ranging from EUR 11,765 per QALY gained in Austria to EUR 43,963 per QALY gained in Italy.Conclusions: For people with T1D managed with is-CGM+MDI not achieving glycemic targets, initiation of the MM780G system was projected to improve long-term clinical outcomes; however, due to differences in healthcare costs between countries, the health economic outcomes differ. In the countries included here, AHCL is likely to be cost-effective relative to is-CGM+MDI for people not achieving glycemic goals with is-CGM+MDI. The ADAPT trial is registered with ClinicalTrials.gov, NCT04235504.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- Type 1 diabetes
- Automated insulin delivery
- Costs and cost analysis
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database